ライフサイエンスコーパス: structure-activity relationship

1 transition state contribute to the atypical structure-activity relationship.

2 in vivo to understand the (+/-)-(11)C-YJH08 structure-activity relationship.

3 re selected to gain insights into the ligand structure-activity relationship.

4 in-carbohydrate conjugates and established a structure-activity relationship.

5 s, rationally improve understanding of their structure-activity relationship.

6 hin a new binding pocket to characterize the structure-activity relationship.

7 studies have enabled to establish a precise structure-activity relationship.

8 s provide the opportunity to define critical structure-activity relationships.

9 resistant SW480/Coti cells revealed distinct structure-activity relationships.

10 loration of bioactive principles of PACs and structure-activity relationships.

11 been cytochrome P450 structure-function and structure-activity relationships.

12 storically enabled a deeper understanding of structure-activity relationships.

13 EH-P inhibition and helps to rationalize the structure-activity relationships.

14 iaryl moieties, providing a new dimension of structure-activity relationships.

15 of isocombretastatin-A4 (iso-CA-4) and their structure-activity relationships.

16 a pharmacophore for SpCas9 inhibition using structure-activity relationships.

17 g intrinsic reaction pathways, for affording structure-activity relationships.

18 ried out to better rationalize the available structure-activity relationships.

19 y proline derivatives, has revealed valuable structure-activity relationships.

20 thus allowing deeper interpretation of known structure-activity relationships.

21 free multienzymatic platform to access these structure-activity relationships.

22 nthesized series of compounds to investigate structure-activity relationships.

23 ansfer and in situ production of HO(*) using structure-activity relationships.

24 cromolar concentrations, showing interesting structure-activity relationships.

25 en better electrocatalytic materials through structure-activity relationships.

26 and 34 analogues were synthesized to explore structure-activity relationships.

27 ates that the approach allows elucidation of structure-activity relationships.

28 cross-links Fzd to LRP6, revealed identical structure-activity relationships.

29 hibitors and gave valuable insights into the structure-activity relationships.

30 synthesis and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of a n

31 To build structure-activity relationships, 45 derivatives of 1 we

32 To further explore its structure-activity relationship, a new series of NAP der

33 We established a multiparametric structure-activity relationship, allowing optimization o

34 xicity parameters for alpha-NETA; identified structure-activity relationships among alpha-NETA domain

35 Structure-activity relationship analyses demonstrate tha

36 Structure-activity relationship analyses led to the iden

37 Moreover, structure-activity relationship analysis and molecular d

38 Structure-activity relationship analysis revealed that t

39 Furthermore, structure-activity relationship analysis with PSMalpha2

40 leiotropic effects and report its systematic structure-activity relationship analysis with the discov

41 Last, using a simple structure-activity relationship analysis, we demonstrate

42 ent modules which are built upon data based (structure activity relationship and classification model

43 y efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues

44 used mutagenesis of tatM2NX to determine the structure-activity relationship and antagonistic mechani

45 The structure-activity relationship and in silico absorption

46 ere, we report a methodology for determining structure-activity relationships and design rules for sp

47 To further elucidate structure-activity relationships and diversify the pyrim

48 Discussion of structure-activity relationships and in vitro biological

49 ry not only enabled the determination of key structure-activity relationships and the identification

50 nt of defined glycans is key to establishing structure-activity relationships and thereby progress in

51 e substrate scope was investigated to obtain structure-activity relationships and to propose a reacti

52 uation of these analogues led to interesting structure-activity relationships and trends and the disc

53 In conjunction with structure-activity relationships and X-ray data, eNTRywa

54 Here, we present the synthesis, structure-activity relationships, and cocrystal structur

55 as a useful tool for the analysis of agonist structure-activity relationships, and for the screening

56 s to provide an overview of the development, structure-activity-relationships, and limitations of com

57 The structure-activity relationship around 6 is described an

58 develop new HAT therapeutics, we report the structure-activity relationships around T. brucei for a

59 Structure-activity relationship assays using additional

60 Herein, we conduct a detailed structure-activity relationship assessment of adenine-ba

61 ese results provide a first insight into the structure-activity relationship at the GABA(A)R beta(+)-

62 Through improved understanding of the structure-activity relationship attributes of fluoroquin

63 lvents, we have established the quantitative structure-activity relationship between the organic stru

64 They exhibit a strong structure-activity relationship, but this is only poorly

65 This work contributes to the study of structure-activity relationship by demonstrating a pract

66 new CDNs bound to STING protein and discuss structure-activity relationship by using quantum and mol

67 ns to the linker structure, insight into the structure-activity relationship could be gained, highlig

68 Moreover, the proposed structure-activity relationships could be exploited in t

69 Structure-activity relationship data suggested and elect

70 nanomole-scale amounts of lead compounds for structure-activity relationship development.

71 Structure-activity relationship-driven expansion of a fr

72 fluorescence-polarization-based assay as the structure-activity-relationship driver.

73 hesis of this series, as well as biochemical structure-activity relationships driving selectivity for

74 ole acetamide scaffolds were synthesized and structure activity relationships elaborated to explore t

75 e been unveiled through evaluation of ligand structure-activity relationships, electrochemical and ki

76 nding hotspots, while the covalent inhibitor structure-activity relationship enabled efficient potenc

77 The structure-activity relationship established that the thi

78 A structure-activity relationship exploration around an is

79 Throughout a structure-activity relationship exploration on the amide

80 anomolar range potency based on a systematic structure-activity relationship exploration.

81 Herein, we report a further structure-activity relationships exploration exploiting

82 binding is also explored, by establishing a structure-activity relationship for binding using a seri

83 of 5HMT and structural analogs demonstrate a structure-activity relationship for furan compounds, sup

84 In general, we established the structure-activity relationship for these promising anti

85 mides and 24 new sulfonamides for a detailed structure-activity relationship for two clinically repre

86 mum number of SNAs needed to capture optimum structure-activity relationships for a given SNA library

87 Structure-activity relationships for a series of small-m

88 ions of this molecule gave insights into the structure-activity relationships for binding and functio

89 S off-targets, we therefore sought to expand structure-activity relationships for harmine's DYRK1A ac

90 wever, this reactive lactone limits informed structure-activity relationships for these bioactive mol

91 e purpose of this review is to summarize the structure-activity relationships for these new NMDAR mod

92 Together, our studies rationalize the structure-activity relationships for these phosphonates

93 f adenophostin A and refine understanding of structure-activity relationships for this Ins(1,4,5)P(3)

94 Herein, we report the design, synthesis, and structure-activity relationships for this novel series o

95 Excavating clear structure-activity relationships from these 'ligandabili

96 Mutagenesis and structure-activity relationships further support the obs

97 The emerged structure-activity relationships guided the discovery of

98 Our structure-activity relationship-guided substitution of E

99 However, drawing potential dependent structure-activity relationships has been complicated, n

100 Structure-activity relationships identified sites in the

101 The structure-activity relationships identified throughout t

102 Structure-activity relationships in both the quinoline a

103 r human therapy, and valuable tools to probe structure-activity relationships in integrins.

104 hput studies to deorphanise and characterise structure-activity relationships in olfaction.

105 unostimulatory reresponses and evaluated the structure-activity relationships in terms of the ability

106 nitrogen, or oxygen substituents and explore structure-activity relationships including those around

107 Detailed structure-activity relationships indicate that their pot

108 Thus, we expanded P2Y(14)R antagonist structure-activity relationship, introducing diverse phy

109 Careful structure-activity relationship investigation guided by

110 Structure-activity relationship investigation of various

111 Structure-activity relationship investigation showed tha

112 Structure-activity relationship investigations revealed

113 The identification and understanding of structure-activity relationships is vital for rational c

114 ribe the chemical optimization and resulting structure-activity relationship, leading to the discover

115 Further investigation of the structure-activity relationship led to the development o

116 vertheless, an insufficient understanding of structure-activity relationships limits experimental dev

117 In this study, we utilized a two-dimensional structure-activity relationship matrix to identify pharm

118 Structure-activity relationship, mechanism of action and

119 their antibacterial activity, biosynthesis, structure-activity relationship, mechanism of action, an

120 cytotoxicity and in vivo antitumor activity, structure-activity relationships, mechanism of action, a

121 A quantitative structure-activity relationship model was employed to vi

122 Quantitative structure-activity relationship models and in vitro assa

123 zation, while 3D-shape or QSAR (quantitative structure-activity relationship) models produced signifi

124 nd kinetic analysis, and any attempt to draw structure-activity relationships must rule out mass tran

125 In the study of these structure-activity relationships, novel pyridine substra

126 Structure activity relationship of the most active compo

127 ein interactions on ASO performance, and the structure activity relationships of PS ASO modification

128 we present the multicomponent synthesis and structure-activity relationship of a series of tetrazole

129 Herein, we report structure-activity relationship of an allosteric modulat

130 To further probe the structure-activity relationship of IRE1alpha-XBP1 activa

131 Herein, we report the structure-activity relationship of pyrazolopyrimidine-ba

132 A focus is on the structure-activity relationship of smNBEs in these react

133 We describe here the structure-activity relationship of the 2,4-disubstituted

134 To rationalize the structure-activity relationship of the best inhibitor 13

135 A structure-activity relationship of the cyclic lipopeptid

136 We elaborated on the structure-activity relationship of the new scaffold and

137 lysis, which gives important guidance to the structure-activity relationship of the system.

138 The structure-activity relationship of these new conjugates

139 emistry exploration, we established a robust structure-activity relationship of these two scaffolds,

140 n a GPCR, obtaining an accurate model of the structure-activity relationship of this chemotype.

141 itic activities, which provide a preliminary structure-activity relationship of this class of compoun

142 Here, the design, synthesis, and structure-activity relationships of 11b analogues are de

143 Here we describe the synthesis and structure-activity relationships of 5,11-dihydro-6H-benz

144 an potentially lead to new insights into the structure-activity relationships of [FeFe]-hydrogenases.

145 The goal of this study was to examine the structure-activity relationships of a series of (18)F-la

146 The provided insights and framework for structure-activity relationships of bivalent degraders a

147 o screening of the GSK Kinetobox library and structure-activity relationships of identified hits led

148 Structure-activity relationships of MycG4 recognition by

149 An extension of the structure-activity relationships of our furan-based cand

150 Given the properties and the structure-activity relationships of PdMo metallene, we s

151 Herein, we extended the structure-activity relationships of PSNCBAM-1 (2) at the

152 Here, we report the structure-activity relationships of the alpha-ketoamide

153 campaigns along with a brief overview of the structure-activity relationships of the diverse chemical

154 inhibitors with plasmepsins, as well as the structure-activity relationships of the inhibitors.

155 inding mode is supported by and explains the structure-activity relationships of these compounds.

156 dioligand binding assays were used to obtain structure-activity relationships of these salts.

157 In this study, we explored the structure-activity relationships of xanthin-8-yl-benzene

158 study adds significant value to our initial structure-activity relationships on a series of zwitteri

159 This study expands the structure-activity relationships on our original series

160 This study reports the first structure-activity relationships on potency and selectiv

161 rational insight into a wealth of historical structure-activity-relationship on its chemical scaffold

162 l can be successfully used to guide chemical structure activity relationship optimization, enabling a

163 Through structure-activity relationship optimization we have arr

164 These analogs produced a structure-activity relationship profile that led to the

165 is minimal structure enable development of a structure-activity relationship profile throughout the c

166 Toward that end, we performed structure-activity relationship profiling of 8 (SLM60314

167 In this study, we report the structure-activity relationship profiling of a 6-amino[1

168 InterPred combines 17 quantitative structure activity relationship (QSAR) models built usin

169 Alternatively, quantitative structure-activity relationship (QSAR) models have been

170 we built machine-learning-based quantitative structure-activity relationship (QSAR) models to predict

171 d of research, broadly known as quantitative structure-activity relationships (QSAR) modeling, has de

172 developed binary and continuous Quantitative Structure-Activity Relationships (QSAR) models implement

173 Modeling approaches such as quantitative structure-activity relationships (QSARs) use molecular d

174 ials is hindered by the lack of quantitative structure-activity relationships (QSARs).

175 ics simulations combined with a quantitative structure activity relationship revealed that the alpha-

176 Details of the design, chemistry, structure-activity relationships, safety, metabolic/phar

177 atives of the 4(3H)-quinazolinones and their structure-activity relationship (SAR) against methicilli

178 The structure-activity relationship (SAR) analysis revealed

179 notypic screening, target deconvolution, and structure-activity relationship (SAR) analysis, a compou

180 Through structure-activity relationship (SAR) analysis, we obtai

181 oxazoline) (BOX) ligand designed via a rapid structure-activity relationship (SAR) analysis.

182 As such, a structure-activity relationship (SAR) campaign was pursu

183 iodistribution determination, a PET-specific structure-activity relationship (SAR) effort, and specif

184 Further systematic structure-activity relationship (SAR) efforts driven by

185 s a prerequisite for establishing a reliable structure-activity relationship (SAR) model.

186 Here, we describe the structure-activity relationship (SAR) of a library of py

187 this discovery, we now describe the initial structure-activity relationship (SAR) of antischistosoma

188 target APJ, there is limited information on structure-activity relationship (SAR) of ELA.

189 as contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidaz

190 ode of action, computer-aided techniques and structure-activity relationship (SAR) optimization studi

191 different compound series with corresponding structure-activity relationship (SAR) progression for a

192 Herein, we report systematic structure-activity relationship (SAR) studies carried ou

193 fication, subsequent medicinal chemistry and structure-activity relationship (SAR) studies identified

194 Structure-activity relationship (SAR) studies indicated

195 Structure-activity relationship (SAR) studies led to the

196 Structure-activity relationship (SAR) studies led to the

197 Further structure-activity relationship (SAR) studies of heteroc

198 escribe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-m

199 Here, we present systematic structure-activity relationship (SAR) studies on the two

200 in a mouse model of AD and detail extensive structure-activity relationship (SAR) studies with 70 an

201 Here we describe a comprehensive structure-activity relationship (SAR) study of a thienop

202 In this work, we present a structure-activity relationship (SAR) study of quinazoli

203 Herein, we report a structure-activity relationship (SAR) study of this comp

204 Here, we report the first comprehensive structure-activity relationship (SAR) study on the scaff

205 uinonate ligand), we describe in this work a structure-activity relationship (SAR) study that involve

206 it-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to

207 Here we present a structure-activity relationship (SAR) study using analog

208 In this proof-of-concept study, an extensive structure-activity relationship (SAR) study was carried

209 To improve the activity of Retro-1, a structure-activity relationship (SAR) study was undertak

210 e results of inhibition assays, as well as a structure-activity relationship (SAR) study.

211 The structure-activity relationship (SAR) trends identified

212 ivatives helped in rationalizing some of the structure-activity relationship (SAR) trends observed.

213 s with PCSK9 as evidenced by thermodynamics, structure-activity relationship (SAR), NMR, and molecula

214 ntagonists, including synthesis and detailed structure-activity relationship (SAR).

215 ned viroporin inhibitor with a comprehensive structure-activity relationship (SAR).

216 sets demonstrating electrostatically driven structure-activity relationships (SAR) from literature d

217 papers have been published and very limited structure-activity relationships (SAR) have been reporte

218 Structure-activity relationships (SAR) in the aurone pha

219 Herein, we detail the synthesis and structure-activity relationships (SAR) of a dipeptide li

220 This review is devoted to the synthesis and structure-activity relationships (SAR) of colchicine alk

221 CHX and analogues, and the establishment of structure-activity relationships (SAR) responsible for t

222 Exploration of structure-activity relationships (SARs) and optimization

223 erful tool to speed up the identification of structure-activity relationships (SARs) and to optimize

224 t engagement are fundamental to establishing structure-activity relationships (SARs) for prospective

225 ber of potent antitumor agents and the first structure-activity relationships (SARs) within this clas

226 In qualitative or quantitative studies of structure-activity relationships (SARs), machine learnin

227 Extensive interrogation of structure-activity relationships (SARs), structure-based

228 diversity of release rates driven by linker structure-activity relationships (SARs).

229 f capsid inhibitors successfully altered the structure-activity-relationships (SARs) of the unwanted

230 The scaffold was designed using a structure-activity relationship screening cascade based

231 Through careful structure activity relationship, several potent and sele

232 An analysis of the (+/-)-YJH08 structure-activity relationship showed that (R)- and (S)

233 Then, structure activity relationship studies allowed drawing

234 Structure-activity relationship studies culminated in th

235 Structure-activity relationship studies demonstrated tha

236 Detailed structure-activity relationship studies enabled optimiza

237 Structure-activity relationship studies evaluated variou

238 Structure-activity relationship studies focused on optim

239 (17) binding site of beta-catenin, extensive structure-activity relationship studies have been conduc

240 Initial structure-activity relationship studies have resulted in

241 Structure-activity relationship studies indicated that t

242 Structure-activity relationship studies involving N-aryl

243 In-depth structure-activity relationship studies led to the disco

244 Thorough structure-activity relationship studies of 3,5-dinitroph

245 Structure-activity relationship studies of HL16 identifi

246 Our initial structure-activity relationship studies on 7-methoxy-4-m

247 Biophysical and biochemical structure-activity relationship studies provided insight

248 Systematic structure-activity relationship studies resulted in lead

249 Structure-activity relationship studies revealed key mot

250 Further chemical synthesis and structure-activity relationship studies revealed seven m

251 Structure-activity relationship studies revealed that in

252 nsive modifications of the bicyclic core and structure-activity relationship studies that were not he

253 Structure-activity relationship studies yielded peptides

254 s identified, which, in tandem with catalyst structure-activity relationship studies, facilitated the

255 CR complexes, previously accumulated peptide structure-activity relationship studies, receptor mutage

256 Based on our structure-activity relationship studies, the molecules w

257 eported EV-D68 inhibitor, dibucaine, through structure-activity relationship studies.

258 facilitated a wide range of mutagenesis and structure-activity relationship studies.

259 hesis of a wide variety of new analogues for structure-activity relationship studies.

260 uman sialin ligands by virtual screening and structure-activity relationship studies.

261 In structure-activity relationships studies, the sigma(1) r

262 Structure-activity-relationship studies and rat pharmaco

263 We now report a new structure-activity relationship study based on structura

264 Our systematic structure-activity relationship study enabled us to iden

265 In this work, the first structure-activity relationship study for CAY scaffold-b

266 The structure-activity relationship study leads to the ident

267 This structure-activity relationship study led to the discove

268 optimize UCF501, we herein report a detailed structure-activity relationship study of 2-arylvinylquin

269 Herein, we report a structure-activity relationship study of a class of nonc

270 Here, we present a structure-activity relationship study of a previously id

271 This study provides a structure-activity relationship study of a series of lip

272 Here, we report further a structure-activity relationship study of AsnEDAs for sel

273 We performed a comprehensive structure-activity relationship study of the conjugates

274 An extensive structure-activity relationship study provides a perspec

275 A cytotoxicity structure-activity relationship study revealed that the

276 In this work, a structure-activity relationship study was carried out wi

277 A structure-activity relationship study was performed for

278 Here, we report the first-ever structure-activity relationship study with the explicit

279 Here, we report a structure-activity relationship study, which led to the

280 alogues were framed around compound 40 for a structure-activity relationship study.

281 compounds were synthesized as a preliminary structure-activity-relationship study.

282 Molecular modeling and structure-activity relationships support binding to HDAC

283 recommended that plasma encompass degradant structure activity relationships to ensure that biologic

284 These breakthroughs enabled structure-activity relationships to be understood and pr

285 Results: Structure-activity relationship trends observed in a LAT

286 These results further define the structure-activity relationships underlying BTN3A1 ligan

287 to reporting this new series and preliminary structure-activity relationship, we demonstrate the valu

288 e-guided and flow chemistry-enabled study of structure-activity relationships, we developed phenylimi

289 Structure-activity relationships were analyzed, and sele

290 s of each compound were defined and the main structure-activity relationships were determined.

291 OX-1 inhibitor, 9c (i472), was developed and structure-activity relationships were explored.

292 Structure-activity relationships were generated by addin

293 ith the protein, and generated a preliminary structure-activity relationship, which enables the devel

294 TCMDC-135051 (1) and efforts to establish a structure-activity relationship with a 7-azaindole-based

295 The aim of the study was to establish the structure-activity relationship within a series of analo

296 of the guide RNA can be used to characterize structure-activity relationships within CRISPR ribonucle

297 Exploration of structure-activity relationships within the series of 1-

298 t a number of cell lines, thus enriching the structure-activity relationships within this class of co

299 hilone molecule and providing new and useful structure-activity relationships within this class of co

300 Chemical optimization based on structure-activity relationships yielded an activator wi